Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer.
Summary of "Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer."
To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. Patients with ovarian cancer had a significantly higher plasma LPA level (n = 81; median (med), 11.53 μmol/l; range, 1.78-43.21 μmol/l) compared with controls with no ovarian pathology (n = 27; med, 1.86 μmol/l; range, 0.94-9.73 μmol/l), and patients with benign ovarian tumor (n = 51; med, 6.17 μmol/l; range, 1.12-25.23 μmol/l; P < 0.001). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics stage. The histological subtype and grade of ovarian cancer did not influence the plasma LPA levels in this study. The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of the disease.
Affiliation
Department of Gynecology and Obstetrics, University Hospital, Sokolská 581, 500 05, Hradec Králové, Czech Republic, sedlakiva@seznam.cz.
Journal Details
This article was published in the following journal.
Name: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
ISSN: 1423-0380
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21061112
- DOI: http://dx.doi.org/10.1007/s13277-010-0123-8
Medical and Biotech [MESH] Definitions
Receptors, Lysophosphatidic Acid
A subfamily of lysophospholipid receptors with specificity for LYSOPHOSPHATIDIC ACIDS.
Wnt2 Protein
A proto-oncogene protein and member of the Wnt family of proteins. It is frequently up-regulated in human GASTRIC CANCER and is a tumor marker (TUMOR MARKERS, BIOLOGICAL) of gastric and COLORECTAL CANCER.
Receptors, Lysophospholipid
A family of G-protein-coupled receptors that bind to specific LYSOPHOSPHOLIPIDS such as lysophosphatidic acid and lysosphinglipids such as sphingosine-1-phosphate. They play an important role in the formation and function of the CARDIOVASCULAR SYSTEM.
Topotecan
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Ovarian Failure, Premature
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
PubMed Articles
Serum Autotaxin is not a Useful Biomarker for Ovarian Cancer.
Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the...
Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.
In ovarian cancer, the molecular targeted chemotherapeutics could increase the efficiency of low-dose radiotherapy while decreasing injury to adjusted organs. In irradiated A2780 human ovarian carcino...
10-15% of invasive epithelial ovarian cancer is attributable to hereditary breast and ovarian cancer. The identification of BRCA1/BRCA2 mutations in women with ovarian cancer allows for accurate predi...
The aim of this study is to evaluate a new tumour marker, HE4, in comparison with CA 125 and the Risk of Ovarian Malignancy Algorithm (ROMA) in healthy women and in patients with benign and malignant...
Lysophosphatidic acid (LPA) stimulates mouse mammary epithelial cell growth.
Lysophosphatidic acid (LPA) is a bioactive phospholipid having diverse effects on various types of tissues. When normal murine mammary gland (NMuMG) cells were cultured in the presence of 0-10 μM LPA...
Clinical Trials
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer. PURPOSE: This clinical trial is...
Tranexamic Acid in Surgery of Advanced Ovarian Cancer
The purpose of the study is to determine if a standardized single dose tranexamic acid given intravenously immediately preoperatively reduces the perioperative bleeding volume and reduces...
The purpose of this study is to improve upon and validate the prognostic and/or predictive accuracy of a drug response marker by the development of improved alternative algorithms based on...
Mesothelin as a New Tumor Marker for Ovarian Cancer
Ovarian cancer became a more and more important disease in recent years due to its first mortality rate of gynecologic malignancies. The incidence of ovarian cancer also increased in recen...
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
RATIONALE: Diagnostic procedures using the drug radiolabeled folic acid and imaging may be effective in detecting ovarian cancer. PURPOSE: Diagnostic trial to study the effectiveness of r...
